These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 39023382)
1. Dual-Engineered Macrophage-Microbe Encapsulation for Metastasis Immunotherapy. Wu L; Qiao L; Zhang S; Qiu J; Du Z; Sun Y; Chang X; Li L; Li C; Qiao X; Yin X; Hua Z Adv Mater; 2024 Sep; 36(36):e2406140. PubMed ID: 39023382 [TBL] [Abstract][Full Text] [Related]
2. Macrophage-mediated tumor-targeted delivery of engineered Wu L; Li L; Li S; Liu L; Xin W; Li C; Yin X; Xu X; Bao F; Hua Z Acta Pharm Sin B; 2022 Oct; 12(10):3952-3971. PubMed ID: 36213533 [TBL] [Abstract][Full Text] [Related]
3. Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy. Wu L; Du Z; Li L; Qiao L; Zhang S; Yin X; Chang X; Li C; Hua Z Signal Transduct Target Ther; 2024 Jan; 9(1):14. PubMed ID: 38195682 [TBL] [Abstract][Full Text] [Related]
4. Two-step enhanced cancer immunotherapy with engineered Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508 [TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery. Zhang X; Yue L; Cao L; Liu K; Yang S; Liang S; Liu L; Zhao C; Wu D; Wang Z; Tian R; Rao L Acta Biomater; 2024 Sep; 186():369-382. PubMed ID: 39097127 [TBL] [Abstract][Full Text] [Related]
6. Engineered bacteria breach tumor physical barriers to enhance radio-immunotherapy. Zhang Y; Liu Y; Li T; Yang X; Lang S; Pei P; Pei H; Chang L; Hu L; Liu T; Yang K J Control Release; 2024 Sep; 373():867-878. PubMed ID: 39097194 [TBL] [Abstract][Full Text] [Related]
7. Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy. Li K; Wang J; Xie Y; Lu Z; Sun W; Wang K; Liang J; Chen X J Nanobiotechnology; 2024 Jul; 22(1):400. PubMed ID: 38972995 [TBL] [Abstract][Full Text] [Related]
8. Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. Ren F; Fan M; Mei J; Wu Y; Liu C; Pu Q; You Z; Liu L Drug Des Devel Ther; 2014; 8():1527-38. PubMed ID: 25284985 [TBL] [Abstract][Full Text] [Related]
9. Tumor-specific delivery of histidine-rich glycoprotein suppresses tumor growth and metastasis by anti-angiogenesis and vessel normalization. Cheng X; Zhang X; Cheng W; Chen J; Ma C; Yang B; Hua ZC Curr Gene Ther; 2014; 14(2):75-85. PubMed ID: 24606115 [TBL] [Abstract][Full Text] [Related]
10. Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella. Nguyen DH; You SH; Ngo HT; Van Nguyen K; Tran KV; Chu TH; Kim SY; Ha SJ; Hong Y; Min JJ Nat Commun; 2024 Aug; 15(1):6680. PubMed ID: 39107284 [TBL] [Abstract][Full Text] [Related]
11. A Salmonella Typhimurium mutant strain capable of RNAi delivery: higher tumor-targeting and lower toxicity. Cheng X; Zhang X; Zhou Y; Zhang C; Hua ZC Cancer Biol Ther; 2014 Aug; 15(8):1068-76. PubMed ID: 24842165 [TBL] [Abstract][Full Text] [Related]
12. Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer Liu L; Zhang J; Gu M; Li G; Ni J; Fan M Anticancer Agents Med Chem; 2020; 20(14):1722-1727. PubMed ID: 32324525 [TBL] [Abstract][Full Text] [Related]
13. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses. Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946 [TBL] [Abstract][Full Text] [Related]
14. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976 [TBL] [Abstract][Full Text] [Related]
15. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer. Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181 [TBL] [Abstract][Full Text] [Related]
16. Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy. Yang Y; Wang Y; Zeng F; Chen Y; Chen Z; Yan F Cell Rep Med; 2024 May; 5(5):101512. PubMed ID: 38640931 [TBL] [Abstract][Full Text] [Related]
17. Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy. Qian H; Fu Y; Guo M; Chen Y; Zhang D; Wei Y; Jin F; Zeng Q; Wang Y; Chai C; Ding S; Cheng W; Chen T Mol Ther; 2022 Aug; 30(8):2817-2827. PubMed ID: 35450820 [TBL] [Abstract][Full Text] [Related]
18. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035 [TBL] [Abstract][Full Text] [Related]
19. Neutrophil-Mediated Tumor-Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy. Liu L; Xin W; Li Q; Huang B; Yin T; Hua S; Yang C; Chen C; Han C; Hua Z Adv Sci (Weinh); 2023 Oct; 10(29):e2301835. PubMed ID: 37565362 [TBL] [Abstract][Full Text] [Related]
20. CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin. Jang Y; Cho YS; Kim A; Zhou X; Kim Y; Wan Z; Moon JJ; Park H ACS Appl Mater Interfaces; 2024 Apr; 16(14):17129-17144. PubMed ID: 38533538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]